Capecitabine in Elderly Patients with Metastatic Breast Cancer
Rita De Sanctis(Humanitas University), Marisa Di Seri(Policlinico Umberto I), Silvia Quadrini(Policlinico Umberto I), Flavia Longo(Policlinico Umberto I), L. De Filippis(Policlinico Umberto I), Iolanda Speranza(Policlinico Umberto I), Ester Del Signore(Policlinico Umberto I), Vincenzo Bianco, Vittoria Lapadula(Policlinico Umberto I), Bruno Gori(Policlinico Umberto I), Maria Luisa Basile(Policlinico Umberto I), Rossella Restuccia(Policlinico Umberto I), Luciano Stumbo(Ospedale San Filippo Neri)
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial
|The Lancet Oncology|2017|493
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial
|The Lancet Neurology|2021|260
Functional changes in Duchenne muscular dystrophy
|Neurology|2011|178
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy
|European Journal of Nuclear Medicine and Molecular Imaging|2019|150